Special Issue

Pharmacology and Medical Uses of Citicoline

Message from the Guest Editor

Citicoline is the international non-proprietary name of cytidine-diphosphocholine (CDP-choline), substance playing a pivotal role in the cellular synthesis of phospholipids. Recently a variant of this substance, citicoline inner salt, has been pronounced a dietary supplement and medicinal food. Over more than fifty years of its medical use, citicoline has proven to be perfectly safe and devoid of any significant side effects. At the same time, there is a continuous influx of new data concerning its effects both on diseased and healthy humans. Previously, citicoline was popularized as a nootropic and neuroprotective drug and is still best known for its activity supporting various aspects of the central nervous system functions in health and some neurological, sensory, and psychiatric diseases. However, this fascinating molecule may evoke important and potentially beneficial effects in other organs as well. e.g., heart and liver. Authors involved in research on citicoline are invited to submit original and review articles on preclinical as well, as clinical studies, to be published in this Special Issue of *Pharmaceuticals*.

Guest Editor

Dr. Paweł Grieb

Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

Deadline for manuscript submissions

closed (30 July 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/54005

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

